Danish biopharmaceutical firm Zealand Pharma has announced that its partner Sanofi has submitted a marketing authorisation application for Lyxumia (lixisenatide) in Europe.
Lixisenatide, developed by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for type 2 diabetes.
Sanofi is set to complete the Phase III development of the drug as a new treatment for the disease.
The marketing authorisation application includes data from the GetGoal Phase III programme, comprising nine studies involving over 4,300 patients.
The trial is intended to provide data for supporting lixisenatide as a treatment for type 2 diabetes.